Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The firm aims to use its platform to guide selection of personalized and immunotherapies for cancer patients and to support drug development.

For many individuals and couples struggling with infertility, the high cost of IVF often makes treatment financially out of reach. The lack of comprehensive insurance coverage for fertility services ...

Insilico achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment ...

Harmony Biosciences Holdings, Inc. (HRMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most ...

Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...